Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience

Hamza S. Gorsi, Paritosh C. Khanna, Mark Tumblin, Lanipua Yeh-Nayre, Mehrzad Milburn, Jennifer D. Elster, John R. Crawford

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Introduction: Bevacizumab-based therapy has been demonstrated to be effective in the treatment of refractory or recurrent pediatric low-grade glioma (LGG); however its efficacy as a single agent is less understood. Methods: We report our experience with single-agent bevacizumab for the treatment of recurrent or refractory LGG treated with either standard 2 week dosing (10 mg/kg/dose every 2 weeks) or with a standard 2 week dosing followed by an increased interval dosing (10 mg/kg/dose every 4 weeks). Results: From 2012 to 2017, 15 patients (five males and 10 females) with recurrent/refractory LGG (nine suprasellar, three thalamic, two brainstem, and one intramedullary spinal cord) were treated with a total of 156 doses of bevacizumab (115 every 2 week dosing, 41 every 4 week dosing, median 10 doses). Patients were refractory to a median of one nonsurgical therapy (range 0–3) prior to treatment with bevacizumab. Twelve of 15 demonstrated radiographic response (three complete, nine partial, and three stable disease). Significant clinical responses including improved visual fields (four), cranial neuropathy (three3), strength (seven), and gait (two) were observed. Bevacizumab was discontinued in 12 patients (resolution, one; disease stability, seven; progression, two; toxicity, one; and other, one) and three patients continue to receive monthly bevacizumab. Eleven patients eventually had radiographic progression (median 5 months, range 0.5–31) without clinical progression, and four of five receiving bevacizumab rechallenge had lpartial response. Conclusion: Single-agent bevacizumab is efficacious in the management of recurrent or refractory pediatric LGG with radiographic and clinical responses similar to those reported for bevacizumab-based therapies.

Original languageEnglish
Article numbere27234
JournalPediatric Blood and Cancer
Issue number9
StatePublished - Sep 2018


  • bevacizumab
  • central nervous system tumors
  • immunotherapy
  • low-grade glioma


Dive into the research topics of 'Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience'. Together they form a unique fingerprint.

Cite this